216 related articles for article (PubMed ID: 30397214)
1. Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib.
Karademir B; Sari G; Jannuzzi AT; Musunuri S; Wicher G; Grune T; Mi J; Hacioglu-Bay H; Forsberg-Nilsson K; Bergquist J; Jung T
Sci Rep; 2018 Nov; 8(1):16318. PubMed ID: 30397214
[TBL] [Abstract][Full Text] [Related]
2. Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect.
Malacrida A; Semperboni S; Di Domizio A; Palmioli A; Broggi L; Airoldi C; Meregalli C; Cavaletti G; Nicolini G
Sci Rep; 2021 May; 11(1):10523. PubMed ID: 34006972
[TBL] [Abstract][Full Text] [Related]
3. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
4. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K; Inukai T; Imamura T; Yano M; Tomoyasu C; Lucas DM; Nemoto A; Sato H; Huang M; Abe M; Kagami K; Shinohara T; Watanabe A; Somazu S; Oshiro H; Akahane K; Goi K; Kikuchi J; Furukawa Y; Goto H; Minegishi M; Iwamoto S; Sugita K
PLoS One; 2017; 12(12):e0188680. PubMed ID: 29236701
[TBL] [Abstract][Full Text] [Related]
5. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
Kubicki T; Bednarek K; Kostrzewska-Poczekaj M; Luczak M; Lewandowski K; Gil L; Jarmuz-Szymczak M; Dytfeld D
Am J Cancer Res; 2022; 12(7):3280-3293. PubMed ID: 35968359
[TBL] [Abstract][Full Text] [Related]
7.
Pokorna Z; Jirkovsky E; Hlavackova M; Jansova H; Jirkovska A; Lencova-Popelova O; Brazdova P; Kubes J; Sotakova-Kasparova D; Mazurova Y; Adamcova M; Vostatkova L; Holzerova K; Kolar F; Simunek T; Sterba M
Clin Sci (Lond); 2019 Aug; 133(16):1827-1844. PubMed ID: 31409729
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib.
Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
[TBL] [Abstract][Full Text] [Related]
9. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Hasinoff BB; Patel D
Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
[TBL] [Abstract][Full Text] [Related]
10. Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib.
Jannuzzi AT; Arslan S; Yilmaz AM; Sari G; Beklen H; Méndez L; Fedorova M; Arga KY; Karademir Yilmaz B; Alpertunga B
Redox Biol; 2020 May; 32():101502. PubMed ID: 32244176
[TBL] [Abstract][Full Text] [Related]
11. Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
Alé A; Bruna J; Morell M; van de Velde H; Monbaliu J; Navarro X; Udina E
Exp Neurol; 2014 Mar; 253():165-73. PubMed ID: 24406455
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy.
Meregalli C; Chiorazzi A; Carozzi VA; Canta A; Sala B; Colombo M; Oggioni N; Ceresa C; Foudah D; La Russa F; Miloso M; Nicolini G; Marmiroli P; Bennett DL; Cavaletti G
Cell Cycle; 2014; 13(4):612-21. PubMed ID: 24335344
[TBL] [Abstract][Full Text] [Related]
13. Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System.
Mina SA; Muhsen IN; Burns EA; Sarfraz H; Pingali SR; Xu J; Hashmi SK
Turk J Haematol; 2021 Aug; 38(3):218-221. PubMed ID: 34190655
[TBL] [Abstract][Full Text] [Related]
14. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
16. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153
[TBL] [Abstract][Full Text] [Related]
19. Critical role of Ca
Tomita S; Sekiguchi F; Deguchi T; Miyazaki T; Ikeda Y; Tsubota M; Yoshida S; Nguyen HD; Okada T; Toyooka N; Kawabata A
Toxicology; 2019 Feb; 413():33-39. PubMed ID: 30552955
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2017 Jul; 17(3):237-250. PubMed ID: 27388042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
